Guangzhou Wondfo Biotech Co., Ltd.

Guangzhou Wondfo Biotech Co., Ltd. is a prominent company listed on the ChiNext board of the Shenzhen Stock Exchange since 2015. Specializing in the research, development, manufacture, and sales of rapid diagnostic reagents and related equipment, Wondfo operates within the in vitro diagnostics (IVD) sector. With 26 years of experience, the company has established multiple technology platforms that enhance its capabilities in producing diagnostic solutions. Wondfo's main business lines include a diverse range of products such as pregnancy tests, infectious disease tests, drug of abuse tests, and chronic disease diagnostics. These products are utilized in various applications, including point-of-care testing, clinical trials, on-site testing, and personal health management. Recognized as a leading enterprise in the point-of-care (POC) field, Wondfo has achieved significant milestones, including being the first Chinese IVD company to pass FDA on-site testing with zero defects. The company is acknowledged as a National High-Tech Enterprise and a core enterprise in the exportation of high-tech medical apparatus and instruments.

Wondfo was the first Chinese IVD enterprise that has passed FDA on-site test with zero-defect, and was recognized as the National High-Tech Enterprise, NDRC (National Development and Reform Commission) Bioengineering High-Tech Industrial Demonstrative Base as well as Mechanical and Electrical and High-Tech Products Exportation Core Enterprise by Ministry of Commerce. At present, Wondfo is one of the leading enterprises in POC field, and is among the first-rate medical apparatus and instruments manufacturer in China.